^
    7ms
    A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Otsuka Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • bendamustine • OPB-111077
    8ms
    STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy (clinicaltrials.gov)
    P1, N=37, Completed, Sidney Kimmel Cancer Center at Thomas Jefferson University | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2024
    Trial completion • Trial completion date • Combination therapy
    |
    Venclexta (venetoclax) • azacitidine • decitabine • OPB-111077
    11ms
    A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL (clinicaltrials.gov)
    P1, N=45, Recruiting, Otsuka Pharmaceutical Co., Ltd. | N=65 --> 45 | Trial completion date: May 2023 --> Mar 2025 | Trial primary completion date: May 2023 --> Mar 2025
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • bendamustine • OPB-111077
    3years
    A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL (clinicaltrials.gov)
    P1, N=65, Recruiting, Otsuka Pharmaceutical Co., Ltd. | Trial completion date: Sep 2021 --> May 2023 | Trial primary completion date: Sep 2021 --> May 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • bendamustine • OPB-111077
    4years
    [VIRTUAL] Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates (ASH 2020)
    The 50% PR rate achieved by OPB-111077, albeit in a few patients, is substantially higher that the 0.7% (1/145) PR rate achieved in a prior phase I trial on all tumor types1. This innovative Phase Ib design selecting patients using a biomarker may enable to rescue drug failures in the future.
    Clinical • P1 data
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    OPB-111077